Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
NCT ID: NCT05169021
Last Updated: 2021-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
15000 participants
INTERVENTIONAL
2021-12-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Efficacy evaluation of amlodipine folic acid tablets:
To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing all-cause stroke in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level.
2. Intensive Antihypertensive Therapy:
To assess the effect of intensive antihypertensive therapy (SBP\<130 mmHg) versus standard antihypertensive therapy (SBP 130-\<140 mmHg) in reducing risk of combined cardio-cerebrovascular events in CSVD patients with hypertension and elevated Hcy level, using two basic anti-hypertensive drugs, amlodipine tablets 5 mg or amlodipine folic acid tablets 5.8 mg.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both Intention-to-treat Analysis (ITT) and Per-protocol set (PPS) were used for analysis.
We will use Kaplan-Meier estimates of the cumulative risk of stroke (ischemic or hemorrhagic) event and combined cardio-cerebrovascular events during follow-up period, with hazards ratios and 95% CI calculated using Cox proportional hazards methods and the log-rank test to evaluate the treatment effect. All statistics will be 2-sided with P\<0.05 considered significant, accounting for interim analyses.
All patients who received study drugs and with at least one safety follow-up record will be included in the safety population. The data for safety evaluation included adverse reactions observed during the trial and changes in laboratory data before and after treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) \<130 mmHg); with amlodipine folic acid 5.8mg.
Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Amlodipine folic acid 5.8mg+standard antihypertensive therapy
This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine folic acid 5.8mg.
Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Amlodipine+intensive antihypertensive therapy
This group will receive intensive antihypertensive therapy (systolic blood pressure(SBP) \<130 mmHg); with amlodipine 5.0mg.
Amlodipine+intensive antihypertensive therapy
Amlodipine tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Amlodipine+standard antihypertensive therapy
This group will receive standard antihypertensive therapy (SBP: 130-140 mmHg); with amlodipine 5.0mg.
Amlodipine+standard antihypertensive therapy
Amlodipine tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Amlodipine+intensive antihypertensive therapy
Amlodipine tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Amlodipine+standard antihypertensive therapy
Amlodipine tablet 5.8mg, taken daily, in the morning after waking.
To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:
1. Add candesartan 4mg;
2. Add indapamide 2.5mg;
3. Increase dose of candesartan to 8mg;
4. Increase dose of amlodipine to 7.5mg-10mg.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Meets any of the following criteria:
1\) Lacunar infarction occurring within the period of seven days up to one year post-infarction, diagnosed by head MRI/CT (meeting modified Fisher criteria\*); 2）Head MRI indicating white matter hyperintensity, 4≥Fazekas score\*≥2; 3）Head MRI indicating white matter hyperintensity, Fazekas=1, combined with old subcortical vascular lacunar infarction;
* For modified Fisher criteria and Fazekas score, see FAITH main study appendix 1 and appendix 6).
3\. Medical recorded history of hypertension. Systolic blood pressure SBP: 130-180 mm Hg on 0 or 1 medication SBP: 130-170 mm Hg on up to 2 medications SBP: 130-160 mm Hg on up to 3 medications. 4. mRS score ≤2; 5. Serum Hcy ≥10 µmol/L or MTHFR 677 TT genotype; 6. Signed informed consent form.
Exclusion Criteria
2. Symptomatic intracranial and extracranial artery stenosis (stenosis ≥50%), or asymptomatic intracranial and extracranial artery stenosis (stenosis≥70%);
3. Patients who have undergone revascularization of the heart, brain, or kidney, or other aortic stenting procedures;
4. Any symptoms of orthostatic hypotension when measuring standing blood pressure, or if standing SBP \<110mmHg;
5. Bilateral renal artery stenosis;
6. Patients who have previously taken candesartan or other angiotensin receptor antagonist (ARB) type medication, indapamide or other similar diuretic type medication, or any medication or health product containing folic acid, and reported adverse reactions;
7. Patients who have indicators for specific antihypertensive medications (e.g. β-blockers after acute myocardial infarction, RAS blockers for prevention of cardiovascular disease, α-blockers for treatment of benign prostate hyperplasia);
8. Within the last three months, regular usage of vitamin supplements containing folic acid, B6, or B12, or usage of folic acid antagonists (e.g. methotrexate);
9. Patients undergoing dialysis or with stage 4-5 chronic kidney disease, or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²;
10. History of epilepsy or currently using anti-epileptic medication;
11. Pregnant and lactating women, or women planning to become pregnant;
12. Life expectancy less than four years;
13. Within the last month, participation in another clinical trial;
14. Any patient determined by the researchers to be unsuitable for the present study.
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tiantan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongjun Wang
President of Beijing Tiantan Hospital, Capital Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yongjun Wang
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jinglin Mo
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, Fu J, Cai Y, Shi X, Zhang Y, Cui Y, Sun N, Li X, Cheng X, Wang J, Yang X, Yang T, Xiao C, Zhao G, Dong Q, Zhu D, Wang X, Ge J, Zhao L, Hu D, Liu L, Hou FF; CSPPT Investigators. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015 Apr 7;313(13):1325-35. doi: 10.1001/jama.2015.2274.
Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004 Feb 4;291(5):565-75. doi: 10.1001/jama.291.5.565.
VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010 Sep;9(9):855-65. doi: 10.1016/S1474-4422(10)70187-3. Epub 2010 Aug 3.
SPS3 Study Group; Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013 Aug 10;382(9891):507-15. doi: 10.1016/S0140-6736(13)60852-1. Epub 2013 May 29.
Croall ID, Tozer DJ, Moynihan B, Khan U, O'Brien JT, Morris RG, Cambridge VC, Barrick TR, Blamire AM, Ford GA, Markus HS; PRESERVE Study Team. Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease: The PRESERVE Randomized Clinical Trial. JAMA Neurol. 2018 Jun 1;75(6):720-727. doi: 10.1001/jamaneurol.2017.5153.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FAITH
Identifier Type: -
Identifier Source: org_study_id